Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pink Sheet Podcast: Regeneron’s COVID Monoclonal Deal, New FDA Advisor, Project Optimus In Cancer Combos

Executive Summary

Pink Sheet reporter and editors discuss the somewhat novel pricing language in Regeneron’s deal with the US government to develop a COVID-19 monoclonal antibody, US FDA Commissioner Robert Califf hiring a new senior advisor, and optimizing dosing in cancer combination therapies.

Pink Sheet Senior Writer Derrick Gingery, Senior Editor Sue Sutter and Executive Editor Nielsen Hobbs consider whether the price controls in Regeneron Pharmaceuticals, Inc.’s new COVID-19 monoclonal contract with the US government could expand beyond COVID-19 (:34), Haider Warraich’s new role at the US Food and Drug Administration (12:10), and the FDA’s Project Optimus moving to combination cancer therapies (21:21).

More On These Topics From The Pink Sheet

Find more episodes on the Pink Sheet podcast page. These and other Citeline podcasts also are available on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn, and Spotify Podcasts, as well as smart speakers if the platforms have been set up as the default podcast provider.

 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel